Welcome to our dedicated page for Phibro Animal SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how antibiotic regulations, feed ingredient prices, and vaccination uptake affect Phibro Animal Health Corporation can mean sifting through hundreds of pages of SEC disclosures. Every 10-K details global livestock trends, and each 8-K might flag new FDA approvals or supply-chain risks. Finding when executives exercise options or which segment drives growth is essential, yet manual searches consume hours. Stock Titan’s AI turns these dense documents into clear intelligence the moment they are filed.
Our engine ingests every Phibro Animal Health quarterly earnings report 10-Q filing, compares it with prior periods, and highlights changes across Animal Health, Mineral Nutrition, and Performance Products. Need to monitor Phibro Animal Health insider trading Form 4 transactions? You’ll get real-time alerts plus plain-English context. The platform clusters documents so you know exactly where to look:
- Phibro Animal Health annual report 10-K simplified for long-term trend review
- Phibro Animal Health Form 4 insider transactions real-time notifications
- Phibro Animal Health executive stock transactions Form 4 with AI commentary
- Phibro Animal Health proxy statement executive compensation distilled
- Phibro Animal Health 8-K material events explained within minutes
Ask, “How are Phibro Animal Health SEC filings explained simply?� or “Where can I find a Phibro Animal Health earnings report filing analysis?”—Stock Titan already has the answer. Our models translate accounting notes, segment metrics, and litigation risks into concise narratives, understanding Phibro Animal Health SEC documents with AI so you don’t have to. From insider alerts to side-by-side ratio comparisons, you’ll gain the clarity needed to act decisively.
Phibro Animal Health Corporation (PAHC) filed a Form 144 reporting a proposed sale of 264,000 shares of Class A Common Stock through Goldman Sachs & Co. LLC with an approximate aggregate market value of $8,250,000. The filing lists 20,367,574 shares outstanding and an approximate sale date of 08/19/2025 on NASD. The shares were acquired on 04/14/2014 in a private placement from Phibro Animal Health Corporation, and the consideration is reported as an exchange of securities. The filer states there were no securities sold by the selling person in the past three months and includes the standard signature representation that the person does not possess undisclosed material adverse information.
Phibro Animal Health Corporation (PAHC) reporting person Larry Lee Miller, Chief Operating Officer, was granted 5,184 restricted stock units (RSUs) on 08/15/2025. After the grant, Mr. Miller beneficially owns 35,184 shares of Class A Common Stock. The RSUs are contingent rights to receive one share per RSU and vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to his continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing discloses a routine equity award to an executive with time-based vesting; no option exercises, sales, or derivative transactions are reported.
Judith Weinstein, Senior Vice President, General Counsel and Corporate Secretary of Phibro Animal Health Corp (PAHC), was granted 3,447 restricted stock units (RSUs) on 08/15/2025. Each RSU represents a contingent right to receive one share of Class A common stock and the reported ownership following the grant is 3,447 shares (direct). The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment through each vesting date. The Form 4 was signed and dated 08/19/2025.
David Glenn, Chief Financial Officer of Phibro Animal Health Corporation (PAHC), received a grant of restricted stock units (RSUs). The Form 4 reports an acquisition dated 08/15/2025 of 4,845 RSUs at a $0 price, bringing his total beneficial ownership to 34,845 shares of Class A Common Stock. The RSUs each represent a contingent right to one share and vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment. The filing was signed by an attorney-in-fact on 08/19/2025. The disclosure reflects a routine executive equity award with time-based vesting.
Jonathan Bendheim, a director of Phibro Animal Health Corp (PAHC), reported acquiring 3,268 restricted stock units (RSUs) on 08/15/2025. These RSUs are contingent rights to receive one share of Class A common stock each and were reported as acquired at a $0 price. Following the reported transaction, Mr. Bendheim beneficially owns 3,268 shares (direct). The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to his continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Daniel M. Bendheim, Executive Vice President, Corporate Strategy and a director of Phibro Animal Health Corporation (PAHC), reported a grant of 3,964 restricted stock units (RSUs) on 08/15/2025. The RSUs represent contingent rights to receive one share of Class A Common Stock per unit and were awarded at $0 purchase price. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Jack Bendheim, who is listed as a director, 10% owner and President and CEO of Phibro Animal Health Corp (PAHC), reported a non‑derivative acquisition on 08/15/2025 of 16,840 restricted stock units (RSUs). Each RSU represents a contingent right to one share of Class A common stock and was reported at a $0 price.
The filing shows 76,320 shares beneficially owned by the reporting person after the transaction. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment. The Form 4 was signed by an attorney‑in‑fact on behalf of Mr. Bendheim on 08/19/2025.
Insider grant of restricted stock units to a senior officer at Phibro Animal Health (PAHC). Lisa Ann Escudero, Senior Vice President, Human Resources, was awarded 2,152 restricted stock units (RSUs) on 08/15/2025. Each RSU represents the contingent right to receive one share of Class A Common Stock and was reported with a transaction code indicating a grant at $0. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, provided the reporting person remains employed through each vesting date. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/19/2025.
Anthony Andolino, Vice President Finance and Treasurer of Phibro Animal Health Corp (PAHC), received an award of 1,793 restricted stock units (RSUs) on 08/15/2025. Each RSU represents a contingent right to one share of Class A common stock and was granted at a $0 price. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Andolino on 08/19/2025.
FAQ
What is the current stock price of Phibro Animal (PAHC)?
What is the market cap of Phibro Animal (PAHC)?
